Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)
- Melita Kenealy*
- , Nigel Patton
- , Robin Filshie
- , Andrew Nicol
- , Shir Jing Ho
- , Mark Hertzberg
- , Tony Mills
- , Ian Prosser
- , Emma Link
- , Linda Cowan
- , Diana Zannino
- , John F. Seymour
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
13
Citations
(Scopus)